

Dame Roma Mitchell Cancer Research Laboratories

About Us

The Dame Roma Mitchell Cancer Research Laboratories (DRMCRL) has an international reputation for innovative research on breast and prostate cancer to improve disease outcomes. We are unique in leveraging similarities between breast and prostate cancers to forge new discoveries and maximise the impact of our research.

Our focus is on how sex steroid hormones (e.g., estrogen, androgen, progesterone) and their receptors drive cancers that arise in the breast and prostate.

The DRMCRL team is recognised for research excellence, attracts competitive national and international research funding, produces high impact scientific publications, translates research findings into clinical practise, and engages in scientific and public outreach initiatives to broadly disseminate new knowledge.

Professor Wayne Tilley, Director

A pioneer of sex hormone receptor action in breast and prostate cancers, Professor Tilley founded the DRMCRL in 2002 with his mentor Professor Villis Marshall, AC, to establish a world-class institution in South Australia dedicated to translational research in the field of hormone-dependent cancers.

Email: wayne.tilley@adelaide.edu.au

Our Consumer Advocates

DRMCRL consumer advocates are cancer survivors who are passionate about research and public awareness. They are integral to our research program and in attracting funding. Through exchange of knowledge and personal experience, they make an invaluable contribution to development of research studies and dissemination of new findings.

Visit Us

The DRMCRL state-of-the-art laboratories are located within the heart of Adelaide's BioMed City precinct, one of the largest hubs of world-class health and biomedical research in the Southern hemisphere.



Level 8, Adelaide Health and Medical Sciences (AHMS) Building Corner North Terrace and George Street Adelaide, South Australia.

Our website: <u>Dame Roma Mitchell Cancer Research</u> <u>Laboratories (DRMCRL) | University of Adelaide</u>

Transforming Endocrine Therapy for Breast and **Prostate Cancer**

Our goal is to understand how sex steroid hormones drive breast and prostate cancer growth and what causes resistance to hormonal therapies commonly used to treat both cancers. This is essential to develop new treatments to improve patient outcomes and quality of life.

Our <u>recent work</u> has provided evidence for the beneficial role of androgens as a breast cancer treatment with rapid implementation of clinical trials in estrogen receptorpositive disease, including those resistant to current standard-of-care treatments.



Our major research effort with national and international collaborators is to develop new generation drugs to rehabilitate the cancer promoting behaviour of steroid receptors and achieve a more durable therapeutic response with improved quality of life.

Critical to performing successful translational research are models that more closely resemble human disease. Enabled by a network of collaborators, the DRMCRL team utilises the most clinically relevant patient-derived models of cancer that preserve the viability and complexity of human tissues.

Our new initiative is to undertake companion canine clinical trials to better understanding drug responses and improve disease outcomes for both dogs and humans. Dogs, like humans, spontaneously develop breast and prostate cancer, making them an excellent model.

DONATE to DRMCRL RESEARCH

Ph +61 8 8313 7856

100% of all donations goes directly to support our talented researchers, especially students and young investigators, to undertake life-changing breast and prostate cancer research and communicate research outcomes to scientists, policy makers and the broader community. Your donation will support staff, students, equipment and materials necessary for our innovative research to improve health outcomes.

Improving disease outcomes for breast and prostate cancers